Vonolazan fumarate, a class 3.1 anti gastric acid drug of Huadong pharmaceutical, China and the United States, entered the Evaluation Center

Vonolazan fumarate, a class 3.1 anti gastric acid drug declared by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., entered the evaluation center on May 5, 2015 Tak-438 (VO noprazan fumarate) is a new oral anti gastric acid drug developed by Takeda pharmaceutical and Otsuka pharmaceutical The drug was just approved for marketing in Japan (trade name: takecab) six months ago (December 26, 2014) After the clinical application was submitted in China in 2012, it is still in the third phase of clinical trials and has not submitted the application for marketing As a potassium competitive acid blocker (p-cab), vonolazan plays a role in the last step of gastric acid secretion in gastric parietal cells It inhibits and terminates gastric acid secretion in advance by inhibiting the binding of K + to H +, K + - ATPase (proton pump) Compared with the current PPIs, vonolazan has no CYP2C19 metabolism, so it shows better efficacy in clinical trials: it is better than lansoprazole in the treatment of gastric ulcer / duodenal ulcer, reflux esophagitis, eradication of Helicobacter pylori, and has similar safety There is no doubt that vonolazan is a gold sucking anti gastric acid drug However, due to the R & D failure of enterprises and fierce competition of PPIs in the market, some people are not optimistic about this drug Even so, domestic enterprises still rushed to apply for vonolazan as soon as possible This is another category 3.1 drug that was declared shortly after the approval of the original research enterprise in China From the first global listing of the original research drug to the domestic imitation declaration, it is not more than half a year before and after It can be seen that, in addition to the declaration upsurge of category 3.1 new drugs, more and more rapid imitation declaration has become another hot trend.